Heterocycle amines and uses thereof

US2016347767A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016347767-A1
Application numberUS-201615006940-A
CountryUS
Kind codeA1
Filing dateJan 26, 2016
Priority dateNov 19, 2010
Publication dateDec 1, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

First claim

Opening claim text (preview).

What is claimed is: 1 . A compound of Formula (I): or a salt, ester, amide, or prodrug thereof, wherein is a single or double bond; W is selected from CH, CH—CH, O, S, NR 6 , and CO; Y is N or CR 9 ; Z is N or C, and Z is N if W is CH and Y is CR 9 ; R 4 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, CO 2 R 6 , SO 3 R 6 , SO 2 R 6 and SO 2 NR 7 R 8 ; R 5 is selected from hydrogen, halogen, OR 6 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 haloheteroalkyl, an optionally substituted C 1 -C 6 alkenyl, and an optionally substituted C 1 -C 6 alkynyl; or R 4 and R 5 are linked to form an optionally substituted non-aromatic ring; each R 6 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted C 1 -C 10 alkyl, an optionally substituted C 1 -C 10 haloalkyl, and an optionally substituted C 1 -C 10 heteroalkyl; each R 7 and R 8 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted C 1 -C 10 alkyl, an optionally substituted C 1 -C 10 haloalkyl, an optionally substituted C 1 -C 10 alkenyl, an optionally substituted C 1 -C 10 alkynyl, and an optionally substituted C 1 -C 10 heteroalkyl, or R 7 and R 8 are linked to form an optionally substituted non-aromatic ring; R 9 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, CO 2 R 6 , SO 3 R 6 , and SO 2 NR 7 R 8 ; A is an optionally substituted aryl or an optionally substituted heteroaryl group; each optionally substituted group is either unsubstituted or substituted with one or more groups independently selected from alkyl, heteroalkyl, alkenyl, alkynyl, haloalkyl, heterohaloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic ring, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, ═O, ═S, amino, and protected derivatives of amino groups. 2 . The compound of claim 1 , wherein R 4 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, CO 2 R 6 , SO 3 R 6 , SO 2 R 6 and SO 2 NR 7 R 8 3 . The compound of claim 1 , wherein if R 4 is pyrazolyl, the pyrazolyl is not substituted with aryl or heteroaryl groups. 4 . The compound of claim 1 , wherein if R 4 is oxazolyl, isoxazolyl, or imidazoyl, the oxazolyl, isoxazolyl, or imidazoyl radical is not substituted with aryl or heteroaryl groups. 5 . The compound of claim 1 , represented by Formula (I-A): or a salt, ester, amide, or prodrug thereof, wherein X is N or CR 5 ′, wherein R 5 ′ is selected from hydrogen, halogen, OR 6 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 haloheteroalkyl, an optionally substituted C 1 -C 6 alkenyl, and an optionally substituted C 1 -C 6 alkynyl; R 1 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , CH 2 NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, an optionally substituted C 1 -C 6 heteroalkyl, CO 2 R 6 , CONR 7 R 8 , SO 3 R 6 , and SO 2 NR 7 R 8 ; R 2 and R 3 are independently selected from hydrogen, halogen, OR 6 , NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, and an optionally substituted C 1 -C 6 heteroalkyl. 6 . The compound of claim 1 , represented by Formula (II): or a salt, ester, amide, or prodrug thereof. 7 . The compound of claim 1 , represented by Formula (III): or a salt, ester, amide, or prodrug thereof, wherein X is N or CR 5 ′, wherein R 5 ′ is selected from hydrogen, halogen, OR 6 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 haloheteroalkyl, an optionally substituted C 1 -C 6 alkenyl, and an optionally substituted C 1 -C 6 alkynyl; R 1 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , CH 2 NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, an optionally substituted C 1 -C 6 heteroalkyl, CO 2 R 6 , CONR 7 R 8 , SO 3 R 6 , and SO 2 NR 7 R 8 ; R 2 and R 3 are independently selected from hydrogen, halogen, OR 6 , NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, and an optionally substituted C 1 -C 6 heteroalkyl. 8 . The compound of claim 1 , wherein W is S. 9 . The compound of claim 7 , wherein X is N. 10 . The compound of claim 1 , wherein Y is CR 9 . 11 . The compound of claim 1 , wherein R 4 is selected from the group consisting of pyridyl, pyrazolyl, cyano, triazolyl, and oxazolyl. 12 . The compound of claim 1 , wherein Y is N. 13 . The compound of claim 1 , wherein R 4 is selected from the group consisting of pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, and C 1 -C 6 al

Assignees

Inventors

Classifications

  • having a nitrogen attached in position 2, e.g. clonidine · CPC title

  • condensed with carbocyclic rings or ring systems · CPC title

  • C07D417/14Primary

    containing three or more hetero rings · CPC title

  • not condensed and containing further heterocyclic rings · CPC title

  • condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016347767A1 cover?
Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
Who is the assignee on this patent?
Ligand Pharm Inc
What technology area does this patent fall under?
Primary CPC classification C07D417/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Dec 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).